Patents Assigned to Inserm
-
Patent number: 12245892Abstract: This method for imaging in real time the propagation of a mechanical wave in an acoustically propagative medium comprises steps of: a) emitting (1000) a mechanical wave in an acoustically propagative medium, using an acoustic source being placed in an emission region of the acoustically propagative medium, b) measuring (1002) voltage signal waveform values at a reception region, using an acoustic measurement unit; c) calculating (1004) acoustic field values in the acoustically propagative medium, between the emission region and the reception region, using a reconstruction algorithm implemented in a signal processing unit, and the signal waveform values measured during step b) d) generating an image, using an image generation device and using the calculated acoustic field values.Type: GrantFiled: January 10, 2018Date of Patent: March 11, 2025Assignees: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ CLAUDE BERNARD LYON, CENTRE LÉON-BÉRARDInventors: William Apoutou N'Djin, Kazuhiro Matsui, Françoise Chavrier, Rémi Souchon
-
Publication number: 20250075247Abstract: The present invention relates to a method for determining the methicillin-resistance properties of a Staphylococcus aureus strain present in a biological sample, the method comprising the following steps: •a) incubating the biological sample containing the Staphylococcus aureus strain for at least 15 minutes in the presence of an antibiotic from the class of beta-lactams selected from the following group: cefoxitin and 6-APA (6-aminopenicillanic acid); •b) isolating the bacteria present in the biological sample; •c) lysing the bacteria and hydrolysing the bacterial proteins in order to obtain a mixture of peptides; and •d) analysing this mixture of peptides by targeted mass spectrometry, the detection of at least one peptide originating from the protein PBP2a (SEQ ID NO. 1) or PBP2c (SEQ ID NO. 2) during this analysis step being indicative of the methicillin resistance of the Staphylococcus aureus strain present in the biological sample.Type: ApplicationFiled: January 11, 2023Publication date: March 6, 2025Applicants: UNIVERSITE CLAUDE BERNARD LYON 1, ECOLE NORMALE SUPERIEURE DE LYON, HOSPICES CIVILS DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (Institut National de la Santé et de la Recherche Médicale), WEEZIONInventors: Jérôme LEMOINE, Francis DEFORET, François VANDENESCH, Olivier DAUWALDER
-
Patent number: 12241125Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: April 25, 2024Date of Patent: March 4, 2025Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 12232843Abstract: The present invention relates to a method for predicting neurodegenerative decline and/or its severity for a patient, especially of cognitive impairment (CI). Strokes and Parkinson's disease are frequently associated with occurrence of long-term cognitive impairment or dementia with still incompletely resolved mechanisms. The discovery of diagnostic and predictive biomarkers thus remains a major challenge. The method of the invention uses radiomics corresponding to texture features extracted from a plurality of previously-acquired medical brain images and correlated with previously-acquired clinical and/or biological data. A classifier is trained beforehand for learning these radiomics, and then operated on radiomics computed from at least one brain image of a patient to generate a score representative of its risks of neurodegenerative decline. By applying this method on a cohort of 160 MCI and non-MCI patients, the inventors show that MCI patients could be early predicted with a mean accuracy of 88%.Type: GrantFiled: March 6, 2019Date of Patent: February 25, 2025Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LILLE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLEInventors: Nacim Betrouni, Régis Bordet
-
Patent number: 12232883Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the models in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.Type: GrantFiled: October 25, 2021Date of Patent: February 25, 2025Assignees: UNIVERSITE D'AIX MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE (AP-HM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Viktor Jirsa, Christophe Bernard, Fabrice Bartolomei, Maxime Guye
-
Patent number: 12234513Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: April 25, 2024Date of Patent: February 25, 2025Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Medicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 12227807Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: April 25, 2024Date of Patent: February 18, 2025Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Publication number: 20250049985Abstract: An adhesive composition including a calcium phosphate ceramic selected from tetracalcium phosphate and alpha-tricalcium phosphate, phosphorylated serine, polydopamine, and an aqueous solvent. Also, a kit for preparing the adhesive composition, which includes the calcium phosphate ceramic, phosphorylated serine, and polydopamine and a method for preparing the adhesive composition, as well as the uses thereof.Type: ApplicationFiled: December 16, 2022Publication date: February 13, 2025Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE, UNIVERSITE DE LILLE, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRALE LILLE INSTITUTInventors: Mathias SCHLUND, Feng CHAI, Joël LYSKAWA, Joël FERRI
-
Patent number: 12223700Abstract: Disclosed is an automatic image analysis method that can be used to automatically recognise at least one rare characteristic in an image to be analysed. The method comprises a learning phase during which at least one convolutional neural network is trained to recognise characteristics, a parameter space of dimension n, in which n?2, is constructed from at least one intermediate layer of the network, a presence probability function is determined for each characteristic in the parameter space from a projection of reference images in the parameter space. During a phase of analysing the image to be analysed, the method comprises a step of recognising the at least one rare characteristic in the image to be analysed on the basis of the presence probability function determined for the at least one rare characteristic.Type: GrantFiled: May 7, 2020Date of Patent: February 11, 2025Assignees: Université Brest Bretagne Occidentale, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventor: Gwenolé Quellec
-
Publication number: 20250040942Abstract: A medical device for penetrating an anatomic structure, e.g., a bone structure, including a processing unit programmed to execute one or more statistical algorithms, e.g., Bayesian-based perforation detection algorithms, with electrical conductivity measured during penetration of an anatomic structure as an input to detect a breach condition, e.g., a spinal canal perforation, based on the measured electrical conductivity. The medical device may include a drill bit having sensing capabilities coupled to the distal end of a robot arm via a power drill unit mounted on the robot arm. The power drill unit may cease transmission of rotary motion to the drill bit upon detection of the breach condition.Type: ApplicationFiled: July 25, 2024Publication date: February 6, 2025Applicants: SpineGuard, Sorbonne Universite, Centre National De La Recherche Scientifique-CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Lilyan LEBLANC, Brahim TAMADAZTE, Thibault CHANDANSON, Elie SAGHBINY
-
Publication number: 20250041221Abstract: The invention relates to a nanoparticle comprising at least one cationic lipid, at least one neutral lipid, and at least one pH sensitive lipid which differs from said cationic lipid, which can be used as a vector for the transport and release of nucleic acids within cells.Type: ApplicationFiled: December 2, 2022Publication date: February 6, 2025Applicants: Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Hospices Civils De Lyon, INSERM (Institut National de la Santé et de la Recherche Médicale), Universita Degli Studi Di VeronaInventors: Giovanna Lollo, Valentina Andretto, David Kryza, Eyad Al Mouazen, Mathieu Repellin, Stéphanie Briancon, Laurent Schaeffer, Jacquier Arnaud, Laurent Coudert
-
Patent number: 12213978Abstract: The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject.Type: GrantFiled: November 15, 2019Date of Patent: February 4, 2025Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAYInventors: Sébastien Apcher, Mouad Alami, Romain Darrigrand, Samir Messaoudi, Valérie Salgues, Zafiarisoa Dolor Renko, Expedite Yen-Pon
-
Patent number: 12215067Abstract: Disclosed is chemical compounds C that are derivatives of norbixin and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal pigment epithelium and more particularly in the context of age-related macular degeneration (AMD) and Stargardt's disease.Type: GrantFiled: December 22, 2020Date of Patent: February 4, 2025Assignees: BIOPHYTIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITEInventors: Laurence Dinan, René Lafont, Pierre Dilda, Serge Camelo, Valérie Fontaine, Christine Balducci, Elodie Monteiro, Louis Guibout, Mathilde Latil, José-Alain Sahel, Stanislas Veillet
-
Patent number: 12208130Abstract: The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists.Type: GrantFiled: March 14, 2018Date of Patent: January 28, 2025Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE LILLE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLEInventors: Paolo Giacobini, Vincent Prevot
-
Patent number: 12208059Abstract: The invention relates to a device (10) for selective regionalization of pulmonary aeration, intended to apply a vacuum over a posterolateral part of a patient's chest wall, said device comprising a rigid or semi-rigid shell (11) intended to selectively surround a posterior part of the patient's chest wall, and a layer of honeycomb material (12) covering an internal wall (13) of the rigid shell, intended to be in contact with the patient's chest wall, said shell comprising at least one through hole (14), intended to be connected to a negative pressure generator.Type: GrantFiled: March 3, 2020Date of Patent: January 28, 2025Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNEInventors: Guillaume Carteaux, Armand Mekontso Dessap
-
Publication number: 20250025541Abstract: An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.Type: ApplicationFiled: July 15, 2024Publication date: January 23, 2025Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEURInventors: Géraldine GROUARD-VOGEL, Eva CONDE GARCÌA, Romain BERTRAND, Noémie CAILLOT, Laurent REBER, Pierre BRUHNS, Vincent SERRA
-
Patent number: 12202860Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: GrantFiled: April 3, 2023Date of Patent: January 21, 2025Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
-
Patent number: 12203943Abstract: The present invention relates to methods for the prediction of the progression of chronic kidney disease in a patient. More particularly, the invention relates to the early prediction of the fast progression of chronic kidney disease using specific biomarker signatures in urine sample of patients.Type: GrantFiled: April 19, 2022Date of Patent: January 21, 2025Assignees: Hoffman-La Roche Inc., INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Melanie Broueilh, Mordi Muorah, Fabiola Terzi
-
Publication number: 20250019771Abstract: A transcriptomic signature based on Human endogenous retroviruses (HERVs) expression to characterize leukemic stem cells. In particular, determining the presence of Leukemic Stem Cells (LSCs) in a patient. In an aspect, determining the presence of, or quantifying, LSCs in a patient. Also, gene-related methods for the identification of high-risk acute myeloid leukemia (AML) patients, methods of predicting response to treatment, methods to evaluate (minimal) residual disease during follow-up, methods to determine relapse risk, and methods of treatment of patients following implementation of the former methods.Type: ApplicationFiled: November 25, 2022Publication date: January 16, 2025Applicants: ERVIMMUNE, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Stéphane DEPIL, Vincent ALCAZER
-
Patent number: 12195437Abstract: The invention relates to compound of formula (I): in particular flavonoid derivatives (quercetin and catechin derivatives), for use in the prevention and/or the treatment of a disease or disorder involving both carbonyl and oxidative stresses.Type: GrantFiled: July 12, 2019Date of Patent: January 14, 2025Assignees: Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier, Ecole Nationale Superieure de Chimie, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Céline Crauste, Espérance Moine, Philippe Brabet, Thierry Durand, Joseph Vercauteren